Literature DB >> 1470817

[Malignancy of uterine sarcoma in comparison with suspect leiomyoma. An anatomo-clinical study of 16 cases].

R V Socolov1, F Z Pricop, D Stratan.   

Abstract

Sarcoma of the uterus accounts for less than 1 per cent of uterine neoplasms but is responsible for more than 15 per cent of deaths. However, histological or clinical malignancy features are poorly understood, in particular those which differentiate sarcomas from leiomyomas. This study involved 16 cases, seen during 8 years in two gynecology clinics in Iasi (Rumania) and chosen according to histological diagnosis. Ten leiomyomas were also chosen for comparison of symptomatology. The malignancy criteria studied--vascular invasion, cellular density, number of mitoses and histological type (most often leiomyosarcoma: 8 out of 16)--were used to compare sarcomas with suspect leiomyomas. The mean age was 50, 7 cases being diagnosed after the menopause. The commonest symptom was metromenorrhagia (11 cases out of 16), but pain was more frequent in leiomyomas (9 out of 10). Treatment was above all surgical, total hysterectomy having the best prognosis (3 deaths out of 8 patients operated upon). Other methods (in particular radiotherapy) not being used immediately after surgery, they could not be studied. In terms of its difficult diagnosis and its high degree of malignancy (9 deaths out of 16), sarcoma must remain an argument in favour of total hysterectomy.

Entities:  

Mesh:

Year:  1992        PMID: 1470817

Source DB:  PubMed          Journal:  Rev Fr Gynecol Obstet        ISSN: 0035-290X


  2 in total

1.  [Relapsing uterine leiomyosarcoma: report of a case].

Authors:  Youssef Benabdejlil; Mohammed Elmarjany; Abdellah Babahabib; Mehdi Elhassani; Hafsa Chahdi; Jaouad Kouach; Driss Rahali Moussaoui; Mohammed Dehayni
Journal:  Pan Afr Med J       Date:  2014-09-24

2.  Uterine sarcomas in Port Harcourt, Nigeria: a 12-year clinico-pathologic study.

Authors:  D Seleye-Fubara; S A Uzoigwe
Journal:  Afr Health Sci       Date:  2007-03       Impact factor: 0.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.